Grafa News and Videos — Page 424

Construction Partners (NASDAQ:ROAD) announced the acquisition of Asphalt Express Enterprises, a liquid asphalt supply and hauling business serving hot-mix asphalt producers in Oklahoma and northern Texas.

CollPlant (NASDAQ:CLGN) signed a definitive agreement to acquire LightSolver, an Israeli deep-tech company developing pure photonic computing technology centered on its Laser Processing Unit platform.

Axsome Therapeutics (NASDAQ:AXSM) announced that the first patient has been dosed in SUMMIT, a Phase 3 trial evaluating AXS-05 for smoking cessation in adult smokers.

Karyopharm Therapeutics (NASDAQ:KPTI) submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval for XPOVIO (selinexor) combined with ruxolitinib to treat patients with myelofibrosis.

Eli Lilly (NYSE:LLY) reported 52-week results from the Phase 3b TOGETHER-PsO and TOGETHER-PsA trials showing Taltz (ixekizumab) plus Zepbound (tirzepatide) improved outcomes compared with Taltz alone in adults with psoriasis or psoriatic arthritis and overweight or obesity.

SAIC (NASDAQ:SAIC) reported fiscal second quarter 2027 revenue of $1.88 billion, up about 6% year over year, including 5.3% organic growth and approximately $20 million from the SilverEdge acquisition.

Pulsenmore (NASDAQ:PLSM) reported first half 2026 revenue of NIS 6.1 million, approximately $2 million, up 53% year over year, with gross profit also increasing 53% to NIS 2.2 million.

BioLineRx (NASDAQ:BLRX) reported second quarter 2026 results with royalty revenue of $0.3 million and a net loss of $4.3 million, compared with a net loss of $3.9 million in the prior-year period.

SLB (NYSE:SLB) signed an agreement to acquire Kelvion, a provider of thermal management and heat exchange technologies, for approximately $3.4 billion in cash to expand its data center infrastructure business.

Lilly (NYSE:LLY) signed a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash, adding precision biologics programs targeting autoimmune and allergic diseases.